Wockhardt Limited
http://www.wockhardt.com/home.aspx
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Wockhardt Limited
US Regulatory Risks, Litigation Likely To Slow FY24 Growth For India’s Top Pharma Firms, Says ICRA
The damage at one of Pfizer’s largest injectables facilities could lead to gains for a few Indian companies, analysts feel. However, regulatory risks, litigation pay-outs and other challenges will slow growth for domestic firms and Indian units of multinationals like Abbott and Pfizer in FY24, says rating agency ICRA as Q1 results begin coming in
Eye On ROI: Will More Indian Firms Re-Calibrate US Market Presence?
Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.
Wockhardt Aims For $12m Annual Savings Through US Restructuring
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice